Normal view MARC view ISBD view

WITHDRAWN: Comparing mental health and addiction characteristics of lesbian/gay/bisexual/transgender/transsexual/queer and non-lesbian/gay/bisexual/transgender/transsexual/queer clients in a residential treatment setting. [electronic resource]

By:

Cullen, Jim

Contributor(s):

Publication details: Journal of substance abuse treatment Oct 2010Description: None p. digitalISSN:

1873-6483

Online resources:

Available from publisher's website

In: Journal of substance abuse treatment p. None

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

1 [Aspirin (acetylsalicylic acid)-induced thrombocytopenia, an unknown adverse effect].
by Lagarce, Laurence
2 Steroid-resistant minimal change nephrotic syndrome in Waldenström macroglobulinemia.
by Sayegh, Johnny
3 Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
by Brousseau, Maud
4 PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).
by Ianotto, Jean-Christophe
5 Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis.
by Moles-Moreau, Marie-Pierre
6 Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.
by Luque Paz, Damien
7 Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.
by Luque Paz, Damien
8 WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis.
by Cottin, Laurane
9 Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.
by Mansier, Olivier
10 Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
by Abgrall, Jean-François
11 Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.
by Cottin, Laurane
12 Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
by Emanuel, Robyn M
13 Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
by Geyer, Holly
14 Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
by Geyer, Holly L
15 Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.
by Scotch, Allison H